New Drug Nearly Doubles Survival for Pancreatic Cancer

A breakthrough drug called daraxonrasib targets the "undruggable" mutation behind 90% of pancreatic cancers, nearly doubling survival time in a major clinical trial.

2 months compared to 6.

7 months with standard chemotherapy.